The World Health Organization (WHO) said on Wednesday a clinical trial in 52 countries would study three anti-inflammatory drugs as potential treatments for COVID-19 patients.
These therapies – artesunate, imatinib and infliximab – were selected by an independent expert panel for their potential in reducing the risk of death in hospitalised COVID-19 patients Artesunate is already used for severe malaria, imatinib for certain cancers, and infliximab for diseases of the immune system such as Crohn’s Disease and rheumatoid arthritis.
The original Solidarity trial last year found that all four treatments evaluated – Remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon – had little or no effect in helping COVID patients. So far, only corticosteroids have been proven effective against severe and critical COVID-19.
NSAIDs: NSAIDs or non-steroidal anti-inflammatory drugs are those medications used for reducing pain (analgesic), decreasing fever (anti-pyretic), preventing blood clots (anti-thrombotic) and decreasing inflammation (anti-inflammatory). NSAIDs are also used to treat non-inflammatory conditions such as migraine, period pain and postoperative pain, and to reduce fever. Some commonly used NSAIDs include:
- aspirin (such as Disprin),
- ibuprofen (such as Nurofen) ,
- naproxen (such as Naprosyn),
- diclofenac (such as Voltaren),
- celecoxib (such as Celebrex).